Global Cord Blood (NYSE:CO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Global Cord Blood (NYSE:CO) in a report released on Friday morning. The firm issued a strong-buy rating on the medical research company’s stock.

Global Cord Blood Price Performance

Shares of Global Cord Blood stock opened at $1.25 on Friday. Global Cord Blood has a 52 week low of $2.03 and a 52 week high of $5.50. The firm has a market capitalization of $151.94 million, a P/E ratio of 1.95 and a beta of 0.16. The firm’s 50 day moving average is $1.54 and its two-hundred day moving average is $1.36.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Northern Trust Corp purchased a new stake in shares of Global Cord Blood in the second quarter valued at about $96,000. Natixis Advisors L.P. grew its holdings in shares of Global Cord Blood by 6.6% during the first quarter. Natixis Advisors L.P. now owns 189,330 shares of the medical research company’s stock worth $729,000 after buying an additional 11,709 shares during the last quarter. Finally, Moneta Group Investment Advisors LLC increased its position in Global Cord Blood by 99,844.5% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 26,093,520 shares of the medical research company’s stock valued at $77,957,000 after acquiring an additional 26,067,412 shares during the period.

Global Cord Blood Company Profile

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.